Press Releases WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 12/03/2026			5-day change	1st Jan Change
91.91 ^CNY	-1.06%		-0.58%	+1.40%

04/03	JPMorgan Chase's long position in H-shares of Wuxi Apptec increases to 8.32% on Feb 26 from 7.14%, HKEX shows	RE
20/02	BlackRock's long position in H-shares of Wuxi Apptec decreases to 4.51% on Feb 16 from 5.22%, HKEX shows	RE

Press Releases

19/01	WuXi AppTec Receives Double 'A' Rating from CDP for Climate Change and Water Security Leadership	AQ
15/01	WuXi AppTec : 2026 JPM Presentation - WuXi AppTec 20260114	PU
12/01	WuXi AppTec : Issues Positive Profit Alert for the Full Year of 2025	PU
21/11	WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry	AQ
26/25/26	WuXi AppTec : Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025; Backlog for Continuing Operations Up 41.2% YoY; Further Raises 2025 Full-year Guidance	PU
26/25/26	WuXi AppTec : Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025; Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance	PU
26/25/26	WuXi AppTec : Unveils Modernized Logo, Reflecting Continued Evolution as a Global Healthcare Partner	PU
26/25/26	WuXi AppTec : 2025 Third Quarterly Results Presentation	PU
26/25/26	WuXi AppTec : Signs Definitive Agreement to Sell China-based Clinical Research Services Business to Hillhouse	PU
14/25/14	BIOSECURE Included In Draft National Defense Authorization Act Of 2026	AQ
26/25/26	WuXi AppTec : 2025 WuXi AppTec Investor Day - Financial Performance	PU
26/25/26	WuXi AppTec : 2025 WuXi AppTec Investor Day - Research Enabling Platforms	PU
28/25/28	WuXi AppTec : Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled	PU
28/25/28	WuXi AppTec : Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY	PU
28/25/28	WuXi AppTec : 2025 Interim Results Presentation	PU
08/25/08	WuXi AppTec Provides Updates on Q2 Share Repurchase, Acquisition Activities	AQ
08/25/08	WuXi AppTec Receives MSCI ESG AAA Leader Rating	AQ
17/25/17	WuXi AppTec : 2024 Annual Results Presentation	PU
17/25/17	WuXi AppTec : Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs	PU
03/25/03	WuXi AppTec : Completes Sale of U.S. Medical Device Testing Operations	PU
17/25/17	WuXi AppTec : Signs Definitive Agreement to Sell U.S. Medical Device Testing Operations to NAMSA	PU
13/25/13	WuXi AppTec : 43th J.P. Morgan Healthcare Conference Main Track Presentation Audio Webcast	PU
06/25/06	WuXi AppTec Listed in TIME Magazine's World's Best Companies in Sustainable Growth 2025	AQ
12/24/12	WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment	AQ
28/24/28	WuXi AppTec : 2024 Third Quarterly Results Presentation	PU